Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$299.8M
Close$
$7.58
32.1% downside
Current Fair Value
32.1% downsideOvervalued by 32.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $299.80 Million |
|---|---|
| Enterprise Value | $259.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 1.07 |
| Outstanding Shares | 34,336,000 |
Return
| Return on Equity | -23.39% |
|---|---|
| Return on Assets | -12.27% |
| Return on Invested Capital | -9.61% |
Valuation & Multiples
| P/E Ratio | -34.16 |
|---|---|
| PEG | 29.13 |
| Price to Sales | 11.16 |
| Price to Book Ratio | 11.16 |
| Enterprise Value to Revenue | 5.07 |
| Enterprise Value to EBIT | -43.46 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$13.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$16.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.16%▼ 56.54% |
|---|---|
| Total Invested | $334,979▼ 99.66% |
| Investors Holding | 3▼ 88.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
CEO: Rostislav Raykov